Bispecific anti-cd19x anti-cd16 antibodies and uses thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Oct 25, 2004
filing date -
Nov 14, 2001
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Described are multivalent multimeric antibodies comprising at least two binding sites specific for the human B cell marker CD19 and human Fc.sub..gamma. receptor III (CD16). Also described are polynucleotides encoding said antibodies as well as vectors comprising said polynucleotides, host cells transformed therewith and their use in the production of said antibodies. Finally, compositions are described comprising any of above mentioned antibodies, polynucleotides or vectors. The pharmaceutical compositions are useful for immunotherapy, preferably against B cell malignancies such as non-Hodgkin's lymphoma.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully